{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:19:56Z","timestamp":1790079596675,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-024-02515-5","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T10:14:20Z","timestamp":1732270460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The effects of Dapagliflozin in a real-world population of HFrEF patients with different hemodynamic profiles: worse is better"],"prefix":"10.1186","volume":"23","author":[{"given":"Francesco","family":"Loria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Mone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Rispoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Di Fonzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Masarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costantino","family":"Mancusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Correale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vitullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Granatiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Mazzeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Mercurio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Di Sarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Falco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Izzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Campanile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Virtuoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Stabile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Bonanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Dattilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Santulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Vecchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Visco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"issue":"Suppl 2","key":"2515_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.2459\/JCM.0000000000001431","volume":"24","author":"M Ciccarelli","year":"2023","unstructured":"Ciccarelli M, Giallauria F, Carrizzo A, Visco V, Silverio A, Cesaro A, Calabro P, De Luca N, Mancusi C, Masarone D, et al. Artificial intelligence in cardiovascular prevention: new ways will open new doors. J Cardiovasc Med (Hagerstown). 2023;24(Suppl 2):e106\u201315.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2515_CR2","doi-asserted-by":"crossref","unstructured":"Visco V, Esposito C, Rispoli A, Di Pietro P, Izzo C, Loria F, Di Napoli D, Virtuoso N, Bramanti A, Manzo M et al: The favourable alliance between CardioMEMS and levosimendan in patients with advanced heart failure. ESC Heart Fail 2024.","DOI":"10.1002\/ehf2.14838"},{"key":"2515_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.874433","volume":"9","author":"V Visco","year":"2022","unstructured":"Visco V, Esposito C, Manzo M, Fiorentino A, Galasso G, Vecchione C, Ciccarelli M. A Multistep Approach to Deal With Advanced Heart Failure: A Case Report on the Positive Effect of Cardiac Contractility Modulation Therapy on Pulmonary Pressure Measured by CardioMEMS. Front Cardiovasc Med. 2022;9: 874433.","journal-title":"Front Cardiovasc Med"},{"key":"2515_CR4","doi-asserted-by":"crossref","unstructured":"Campanile A, Visco V, De Carlo S, Ferruzzi GJ, Mancusi C, Izzo C, Mongiello F, Di Pietro P, Virtuoso N, Ravera A et al: Sacubitril\/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients. Life (Basel) 2023, 13(5).","DOI":"10.3390\/life13051174"},{"issue":"18","key":"2515_CR5","first-page":"e876","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e876\u201394.","journal-title":"Circulation"},{"issue":"36","key":"2515_CR6","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"37","key":"2515_CR7","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339.","journal-title":"Eur Heart J"},{"issue":"4","key":"2515_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"11","key":"2515_CR9","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMc1600827","volume":"374","author":"PA Sarafidis","year":"2016","unstructured":"Sarafidis PA, Tsapas A. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2016;374(11):1092.","journal-title":"N Engl J Med"},{"issue":"21","key":"2515_CR10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"12","key":"2515_CR11","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"4","key":"2515_CR12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","volume":"143","author":"M Packer","year":"2021","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, et al. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation. 2021;143(4):326\u201336.","journal-title":"Circulation"},{"issue":"16","key":"2515_CR13","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","volume":"144","author":"M Packer","year":"2021","unstructured":"Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, et al. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation. 2021;144(16):1284\u201394.","journal-title":"Circulation"},{"issue":"9","key":"2515_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanhl.2024.08.001","volume":"5","author":"P Mone","year":"2024","unstructured":"Mone P, Ciccarelli M, Jankauskas SS, Guerra G, Vecchione C, Visco V, Santulli G. SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug? Lancet Healthy Longev. 2024;5(9): 100632.","journal-title":"Lancet Healthy Longev"},{"issue":"9","key":"2515_CR15","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1161\/HYPERTENSIONAHA.123.20598","volume":"80","author":"G Santulli","year":"2023","unstructured":"Santulli G, Varzideh F, Forzano I, Wilson S, Salemme L, de Donato A, Lombardi A, Rainone A, Nunziata L, Jankauskas SS, et al. Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart. Hypertension. 2023;80(9):1800\u20139.","journal-title":"Hypertension"},{"key":"2515_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.107055","volume":"200","author":"P Mone","year":"2024","unstructured":"Mone P, Guerra G, Lombardi A, Illario M, Pansini A, Marro A, Frullone S, Taurino A, Sorriento D, Verri V, et al. Effects of SGLT2 inhibition via empagliflozin on cognitive and physical impairment in frail diabetic elders with chronic kidney disease. Pharmacol Res. 2024;200: 107055.","journal-title":"Pharmacol Res"},{"issue":"24","key":"2515_CR17","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJM197612092952406","volume":"295","author":"JS Forrester","year":"1976","unstructured":"Forrester JS, Diamond G, Chatterjee K, Swan HJ. Medical therapy of acute myocardial infarction by application of hemodynamic subsets (first of two parts). N Engl J Med. 1976;295(24):1356\u201362.","journal-title":"N Engl J Med"},{"issue":"2","key":"2515_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0002-9149(77)80182-3","volume":"39","author":"JS Forrester","year":"1977","unstructured":"Forrester JS, Diamond GA, Swan HJ. Correlative classification of clinical and hemodynamic function after acute myocardial infarction. Am J Cardiol. 1977;39(2):137\u201345.","journal-title":"Am J Cardiol"},{"issue":"10","key":"2515_CR19","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/echo.13642","volume":"34","author":"AE Abbas","year":"2017","unstructured":"Abbas AE, Khoury Abdulla R, Aggrawal A, Crile J, Lester SJ, Boura J. A novel echocardiographic hemodynamic classification of heart failure based on stroke volume index and left atrial pressure. Echocardiography. 2017;34(10):1417\u201325.","journal-title":"Echocardiography"},{"issue":"4","key":"2515_CR20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.119.009939","volume":"13","author":"D Mele","year":"2020","unstructured":"Mele D, Pestelli G, Dini FL, Dal Molin D, Smarrazzo V, Trevisan F, Luisi GA, Ferrari R. Novel Echocardiographic Approach to Hemodynamic Phenotypes Predicts Outcome of Patients Hospitalized With Heart Failure. Circ Cardiovasc Imaging. 2020;13(4): e009939.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"2","key":"2515_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10741-019-09826-w","volume":"25","author":"D Mele","year":"2020","unstructured":"Mele D, Andrade A, Bettencourt P, Moura B, Pestelli G, Ferrari R. From left ventricular ejection fraction to cardiac hemodynamics: role of echocardiography in evaluating patients with heart failure. Heart Fail Rev. 2020;25(2):217\u201330.","journal-title":"Heart Fail Rev"},{"issue":"10254","key":"2515_CR22","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819\u201329.","journal-title":"Lancet"},{"issue":"1","key":"2515_CR23","doi-asserted-by":"publisher","first-page":"6665","DOI":"10.1038\/s41598-020-63801-2","volume":"10","author":"MV Polito","year":"2020","unstructured":"Polito MV, Silverio A, Rispoli A, Vitulano G, Auria F, De Angelis E, Loria F, Gigantino A, Bonadies D, Citro R, et al. Clinical and echocardiographic benefit of Sacubitril\/Valsartan in a real-world population with HF with reduced ejection fraction. Sci Rep. 2020;10(1):6665.","journal-title":"Sci Rep"},{"issue":"10","key":"2515_CR24","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.5603\/KP.2016.0141","volume":"74","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Kardiol Pol. 2016;74(10):1037\u2013147.","journal-title":"Kardiol Pol"},{"key":"2515_CR25","unstructured":"McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA et al: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 14(8):803\u2013869."},{"issue":"1","key":"2515_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10741-019-09828-8","volume":"25","author":"P Severino","year":"2020","unstructured":"Severino P, Maestrini V, Mariani MV, Birtolo LI, Scarpati R, Mancone M, Fedele F. Structural and myocardial dysfunction in heart failure beyond ejection fraction. Heart Fail Rev. 2020;25(1):9\u201317.","journal-title":"Heart Fail Rev"},{"issue":"5","key":"2515_CR27","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","volume":"43","author":"J Butler","year":"2022","unstructured":"Butler J, Packer M, Filippatos G, Ferreira JP, Zeller C, Schnee J, Brueckmann M, Pocock SJ, Zannad F, Anker SD. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J. 2022;43(5):416\u201326.","journal-title":"Eur Heart J"},{"issue":"2","key":"2515_CR28","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/ehf2.13779","volume":"9","author":"FL Dini","year":"2022","unstructured":"Dini FL, Carluccio E, Bitto R, Ciccarelli M, Correale M, D\u2019Agostino A, Dattilo G, Ferretti M, Grelli A, Guida S, et al. Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril\/valsartan. ESC Heart Fail. 2022;9(2):1107\u201317.","journal-title":"ESC Heart Fail"},{"issue":"6","key":"2515_CR29","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/jcpt.13205","volume":"45","author":"H Kim","year":"2020","unstructured":"Kim H, Lee SH, Cho JH, Lee H, Yim HW, Yoon KH, Kim HS. Discontinuation rate and reason for discontinuation after sodium-glucose cotransporter 2 inhibitor prescription in real clinical practice. J Clin Pharm Ther. 2020;45(6):1271\u20137.","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"2515_CR30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","volume":"77","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F, et al. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2021;77(3):243\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2515_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","volume":"17","author":"F Soga","year":"2018","unstructured":"Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol. 2018;17(1):132.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"2515_CR32","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"MMY Lee","year":"2021","unstructured":"Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, Berry C, Chong V, Coyle L, Docherty KF, et al. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Circulation. 2021;143(6):516\u201325.","journal-title":"Circulation"},{"issue":"8","key":"2515_CR33","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/ejhf.2884","volume":"25","author":"DA Pascual-Figal","year":"2023","unstructured":"Pascual-Figal DA, Zamorano JL, Domingo M, Morillas H, Nunez J, Cobo Marcos M, Riquelme-Perez A, Teis A, Santas E, Caro-Martinez C, et al. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study. Eur J Heart Fail. 2023;25(8):1352\u201360.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"2515_CR34","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020\u201331.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2515_CR35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3892\/etm.2024.12461","volume":"27","author":"Y Han","year":"2024","unstructured":"Han Y, Li YF, Ye CW, Gu YY, Chen X, Gu Q, Xu QQ, Wang XM, He SM, Wang DD. Effects of dapagliflozin on body weight in patients with type 2 diabetes mellitus: Evidence-based practice. Exp Ther Med. 2024;27(4):173.","journal-title":"Exp Ther Med"},{"issue":"6","key":"2515_CR36","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1093\/ejechocard\/jen147","volume":"9","author":"S Gupta","year":"2008","unstructured":"Gupta S, Khan F, Shapiro M, Weeks SG, Litwin SE, Michaels AD. The associations between tricuspid annular plane systolic excursion (TAPSE), ventricular dyssynchrony, and ventricular interaction in heart failure patients. Eur J Echocardiogr. 2008;9(6):766\u201371.","journal-title":"Eur J Echocardiogr"},{"key":"2515_CR37","doi-asserted-by":"crossref","unstructured":"Popescu BA, Antonini-Canterin F, Temporelli PL, Giannuzzi P, Bosimini E, Gentile F, Maggioni AP, Tavazzi L, Piazza R, Ascione L et al: Right ventricular functional recovery after acute myocardial infarction: relation with left ventricular function and interventricular septum motion. GISSI-3 echo substudy. Heart 2005, 91(4):484\u2013488.","DOI":"10.1136\/hrt.2003.028050"},{"key":"2515_CR38","doi-asserted-by":"crossref","unstructured":"Mustapic I, Bakovic D, Susilovic Grabovac Z, Borovac JA: Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction. J Clin Med 2022, 12(1).","DOI":"10.3390\/jcm12010042"},{"issue":"5","key":"2515_CR39","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1002\/ehf2.13982","volume":"9","author":"V Visco","year":"2022","unstructured":"Visco V, Radano I, Campanile A, Ravera A, Silverio A, Masarone D, Pacileo G, Correale M, Mazzeo P, Dattilo G, et al. Predictors of sacubitril\/valsartan high dose tolerability in a real world population with HFrEF. ESC Heart Fail. 2022;9(5):2909\u201317.","journal-title":"ESC Heart Fail"},{"issue":"27","key":"2515_CR40","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1093\/eurheartj\/ehac210","volume":"43","author":"L Shen","year":"2022","unstructured":"Shen L, Jhund PS, Docherty KF, Vaduganathan M, Petrie MC, Desai AS, Kober L, Schou M, Packer M, Solomon SD, et al. Accelerated and personalized therapy for heart failure with reduced ejection fraction. Eur Heart J. 2022;43(27):2573\u201387.","journal-title":"Eur Heart J"},{"issue":"15","key":"2515_CR41","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"9","key":"2515_CR42","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1681\/ASN.2021020167","volume":"32","author":"GM Chertow","year":"2021","unstructured":"Chertow GM, Vart P, Jongs N, Toto RD, Gorriz JL, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Sjostrom CD, et al. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. J Am Soc Nephrol. 2021;32(9):2352\u201361.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2515_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa205","volume":"4","author":"V Visco","year":"2020","unstructured":"Visco V, Esposito C, Vitillo P, Vecchione C, Ciccarelli M. It is easy to see, but it is better to foresee: a case report on the favourable alliance between CardioMEMS and levosimendan. Eur Heart J Case Rep. 2020;4(4):1\u20135.","journal-title":"Eur Heart J Case Rep"},{"issue":"18","key":"2515_CR44","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","volume":"140","author":"ME Nassif","year":"2019","unstructured":"Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, McGuire DK, Pitt B, Scirica BM, Austin B, et al. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation. 2019;140(18):1463\u201376.","journal-title":"Circulation"},{"issue":"8","key":"2515_CR45","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1161\/HYPERTENSIONAHA.122.19586","volume":"79","author":"P Mone","year":"2022","unstructured":"Mone P, Varzideh F, Jankauskas SS, Pansini A, Lombardi A, Frullone S, Santulli G. SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients. Hypertension. 2022;79(8):1633\u201343.","journal-title":"Hypertension"},{"issue":"3","key":"2515_CR46","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10741-020-10038-w","volume":"26","author":"A Fathi","year":"2021","unstructured":"Fathi A, Vickneson K, Singh JS. SGLT2-inhibitors; more than just glycosuria and diuresis. Heart Fail Rev. 2021;26(3):623\u201342.","journal-title":"Heart Fail Rev"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02515-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02515-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02515-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T11:05:09Z","timestamp":1732273509000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02515-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2515"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02515-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"423"}}